Loading organizations...
§ Venture Capital · Suzhou, China
InnoPinnacle Fund is an investment firm.
InnoPinnacle Fund operates as an investment fund primarily focused on early-stage ventures within the biotechnology and pharmaceutical sectors. The fund is structured as an early-stage RMB fund, initiated and led by Innovent Bio. It holds a Capital Markets Services License as a Venture Capital Fund licensee, indicating its regulated status in certain jurisdictions.
Headquartered in Suzhou, China, InnoPinnacle Fund actively deploys capital into companies developing drugs and other biotechnological innovations. Its investment strategy supports the growth of emerging companies in these specialized fields.
InnoPinnacle Fund was initiated and is led by Innovent Bio, operating as an early-stage RMB fund.
InnoPinnacle Fund is a venture capital fund located in Suzhou, China.
InnoPinnacle Fund was initiated and is led by Innovent Bio, operating as an early-stage RMB fund.
InnoPinnacle Fund is a venture capital fund located in Suzhou, China.
InnoPinnacle Fund is an investment firm specializing in venture capital, with a strategic emphasis on the biotechnology and pharmaceutical industries. The fund is recognized as an early-stage RMB fund, a designation that highlights its focus on nascent companies and its primary currency of operation. Innovent Bio plays a pivotal role in its structure, having initiated and taken the lead in its management.
The fund's investment activities are concentrated on enterprises involved in drug discovery, development, and other advanced biotechnological applications. This sector-specific approach allows InnoPinnacle Fund to leverage specialized knowledge and networks to identify and support promising innovations. Its portfolio includes companies that have successfully secured significant funding rounds, demonstrating its capacity to back growth-oriented ventures.
InnoPinnacle Fund maintains its primary operational base in Suzhou, China. This location positions it within a region known for its growing life sciences ecosystem, facilitating access to a pipeline of potential investment opportunities. The fund also operates under regulatory oversight, holding a Capital Markets Services License as a Venture Capital Fund licensee.
Through its investments, InnoPinnacle Fund aims to contribute to the advancement of medical science and technology. Its involvement in funding rounds for companies like Bluejay Therapeutics and AusperBio illustrates its commitment to fostering innovation in the biotech space, supporting the development of new therapies and solutions.
InnoPinnacle Fund has 3 tracked investments across 3 companies. The latest tracked deal is $35.0M Seed in Spurious in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Biotrack Capital, Hankang Capital, Lichen Capital, LongRiver Investments |
| Dec 1, 2024 | AusperBio | $73.0M Series B | — | 01 Advisors, Abstract Ventures, Addition, B8, Bessemer Venture Partners, General Catalyst, Qiming Venture Partners, Redpoint Ventures, South Park Commons, Y Combinator, CDH Investments, Sherpa Capital |
| Aug 1, 2022 | Bluejay Therapeutics | $41.0M Series B | Alon Lazarus IN Remembrance | Digitalis Ventures, Rivervest, Ting JIA (tj), Nancy Hong, Bill Rutter, Yonjin Capital |